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BACKGROUND: SB939 is an orally available, competitive histone deacetylase (HDAC) inhibitor selective for class I, II and IV histone
deacetylases. Preclinical evaluation of SB939 revealed a profile suggesting improved efficacy compared to other HDAC inhibitors.
This phase I study was carried out to determine the safety, dose-limiting toxicity, recommended phase II dose (RPTD), as well as
pharmacokinetic (PK) and pharmacodynamic (PD) profiles of SB939 in a daily   5 schedule in advanced solid tumours.
METHODS: Sequential dose-escalating cohorts of patients were enrolled into 8 dose levels. At dose level 1, SB939 was taken on days
1–3 and 15–17 every 4 weeks, then on days 1–5 and 15–19 for other dose levels. Detailed PK sampling was performed in cycle 1,
days 1 and 5. Peripheral blood mononuclear cells (PBMCs) were collected on cycle 1 at various time points for determination of
acetylated histone H3 (AcH3) levels.
RESULTS: In total, 38 patients received a total of 96 cycles of treatment. The maximal administered dose was 90mg and the RPTD was
60mg given 5 consecutive days every 2 weeks. The most frequent non-hematologic adverse events (AEs) of at least possible
attribution to SB939 were fatigue, nausea, vomiting, anorexia and diarrhoea. Pharmacokinetic analysis showed dose-proportional
increases in AUC across the doses evaluated. Elimination half-life was 5.6–8.9h. There was no clear relationship between AcH3
changes and dose level or anti-tumour response.
CONCLUSIONS: SB939 is well tolerated in patients with advanced solid tumours. The RPTD of this drug is 60mg on a schedule
of 5 consecutive days every 2 weeks. The toxicities of SB939 are consistent with other HDAC inhibitors.
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Epigenetic changes that occur through chromatin modulation
regulate the accessibility of gene promoters to the transcription
and replication machinery (Strahl and Allis, 2000; Johnstone and
Licht, 2003). Chromatin modulation and its associated effects on
gene expression are controlled by opposing effects of two families
of enzymes: histone acetylase transferases (HATs) and histone
deacetylases, known as HDACs (Chan et al, 2001; Carey and La
Thangue, 2006). Histone deacetylation is an important epigenetic
event implicated in the development and progression of cancer and
provides an attractive anti-tumour therapeutic platform (Pandolfi,
2001; Timmermann et al, 2001; Chambers et al, 2003). The HDAC
family is divided into zinc-dependent (class I, II and IV) and
zinc-independent, nicotinamide-adenine dinucleotide-dependent
(class III) categories (Stimson et al,2 0 0 9 ) .A tp r e s e n t ,m o s tH D A C
inhibitors being developed as anti-cancer agents target class I, II and
IV enzymes and there is increasing interest in the class III family.
The accumulation of acetylated proteins through HDAC inhibition
results in a variety of cell type-dependent responses, such as
differentiation, induction of cell cycle arrest, apoptosis, as well as
altered patterns of gene expression.
SB939 (3-[2-butyl-1-(2-diethylaminoethyl)-1H-benzoimidazol-
5-yl]-N-hydroxyacrylami-hydrochloride) is an orally available,
competitive inhibitor of HDAC. In vitro studies showed that
SB939 has 41000-fold selectivity for class I, II and IV HDACs
compared with class III HDACs with no effects on other zinc-
binding enzymes (Novotny-Diermayr et al, 2010). The in vitro
evaluation of SB939 also showed significant anti-proliferative
activities against a wide variety of cell lines. Immunoblotting
techniques showed that SB939 treatment of cancer cells results in
the accumulation of acetylated histone H3 (AcH3) and acetylated
a-tubulin, as well as increased expression levels of the cyclin
dependant kinase inhibitor p21 (Novotny-Diermayr et al, 2010).
SB939 has favourable pharmacokinetic (PK) properties in
animal pre-clinical models, with 44-fold increased bioavailability
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sand 3.3-fold longer half-life compared with suberoylanilide
hydroxamic acid (vorinostat), another HDAC inhibitor active in
human malignancies. SB939 also demonstrated prolonged drug
accumulation and more sustained inhibition of histone deacety-
lation in tumour tissues compared with vorinostat in preclinical
experiments. In HCT-116 cells, SB939 was more effective than
vorinostat. These excellent PK and pharmacodynamic (PD) pro-
perties translated into a dose-dependent anti-tumour efficacy in
several experimental solid tumours models, including xenograft
models of colon (HCT-116), ovarian (A2780) and prostate (PC3,
DU145) carcinomas, as well as murine models of acute myeloid
leukaemia (MV4-11, HL-60) and B cell lymphoma (Novotny-
Diermayr et al, 2010).
Based on the relevance of HDACs as cancer therapeutic targets,
and the encouraging preclinical profile of SB939, the NCIC
CTG conducted a phase I trial in patients with advanced solid
tumours. The primary objective was to determine the RPTD, safety
and tolerability of SB939 given on a daily 5 every other week
schedule. Secondary objectives included the assessments of PK and
PD changes in peripheral blood mononuclear cells (PBMCs) and
preliminary anti-tumour efficacy. The choice for the human
starting dose of 10mg was based on 1/10th of the no observed
adverse effect level of the dog species at 60mgm
 2 per day (3 days
per week in a 28-day cycle), rounded to the nearest available fixed
dose capsule size. In this study, the every other week schedule was
evaluated because trials of other HDAC inhibitors suggest fatigue
is a common AE that can prohibit continuous dosing. Therefore,
a schedule of continuous 5-day dosing on alternate weeks
was deemed appropriate to try to avoid dosing interruptions. In
addition to this NCIC CTG study, another phase I trial evaluating
three times weekly dosing 3 out of 4 weeks was undertaken by
investigators in Singapore (Yong et al, 2008, 2009).
METHODS
Patient eligibility
Patients were eligible if they had histologically or cytologically
documented advanced solid malignancy, refractory to standard
therapy or for which conventional therapy was not effective. Other
key eligibility criteria included: age X18 years; Eastern Coopera-
tive Oncology Group performance status 0–2; adequate haemato-
logic, hepatic and renal functions (absolute neutrophil count
X1.5 10
9l
 1, platelets X100 10
9l
 1, bilirubin pupper limit of
normal, aspartate transaminase (AST)/alanine transaminase (ALT)
p2.5 times upper limit of normal or o5 times upper limit
of normal if documented liver metastases, creatinine p1.2 times
upper limit of normal (or calculated creatinine clearance of
X60mls
 1 via Cockroft and Gault formula); adequate cardiac
function (LVEF of X50%, Troponin I or T pupper limits of
normal and a corrected QT (QTc) interval of p450ms). Prior
therapy, except for HDAC inhibitors, was allowed, but there must
be a 4-week interval between previous systemic/radiotherapy and
initiation of study drug. Patients with documented central nervous
system metastasis, pathologic arrhythmia requiring active treat-
ment within the past 12 months or with significant co-morbidities
were excluded from the study. As well, patients on agents with a
known risk of Torsades de Pointes were excluded. The institutional
review board of both participating centres approved the study,
which was conducted in accordance with the federal and
institutional guidelines.
Study design and patient evaluation
This was a two-centre, single-agent, open-label dose-escalation
phase I study in which SB939 was administered orally in an empty
stomach (X1h before a meal or 2h after). SB939 was administered
in an empty stomach as there were no data available on the effect
of food intake on drug absorption at the time the trial was
initiated. Study drug was administered at a starting dose of 10mg
on days 1–3 and 15–17 for the first dose level while for subsequent
dose levels, treatment was administered on days 1–5 and 15–19,
within a 28-day cycle. No intra-patient dose escalation was
allowed. Dose escalation followed the standard 3þ3 rule, but the
protocol did allow up to four patients to be entered in the first
stage of accrual at each dose level. The maximum administered
dose was defined as the dose level at which X2/3 or X2/6 patients
experienced dose-limiting toxicity (DLT). The next lower dose
would normally be declared the RPTD for expansion to confirm
the tolerability and PK and/or PD relationships at this dose level.
In cycle 1, patients were seen on days 1, 5, 8, 15, 19, 22 and
weekly in subsequent cycles for laboratory studies and assessment
of toxicity. As HDAC inhibitors have been associated with cardiac
effects, electrocardiographs (ECGs) were undertaken pre- and
post-dose in cycle 1 on days 1, 5, 15, 19 and on day 1 of subsequent
cycles. In addition, troponin levels were obtained on days 1, 5, 15
in cycle 1 and on day 1 of subsequent cycles. Toxicity was graded
using the National Cancer Institute Common Terminology Criteria
for Adverse Events version 3.0 (http://ctep.cancer.gov/protocol
Development/electronic_applications/ctc.htm#ctc_30). Dose-limit-
ing toxicities were defined as AEs occurring during the first cycle
of SB939 administration and fulfilling one of the following criteria:
grade 4 neutropenia lasting X5 days or associated with fever or
infection; thrombocytopenia Xgrade 3 or thrombocytopenic
bleeding Xgrade 3; nausea/vomiting Xgrade 3 despite anti-emetic
therapy; other major organ toxicity of Xgrade 3 and delay in
starting cycle 2 of 42 weeks or missing two or more consecutive
doses within a cycle due to treatment-related AEs of laboratory
abnormalities.
For patients with measurable disease at baseline, response was
assessed using the Response and Evaluation Criteria in Solid
Tumours version 1.0 (Therasse et al, 2000).
Dose modification
Patients who experienced any DLT were delayed by 1-week
intervals until recovery and could continue on study drug with a
reduction of one dose level. If no recovery occurred after a delay of
2 weeks from the next scheduled 5-day treatment, patients were
discontinued from protocol treatment. In addition, patients must
have an absolute neutrophil count of X1.5 10
9l
 1 and a platelet
level of X100 10
9l
 1 before day 1 and 15 dosing. SB939 was held
if grade 2 QTc interval prolongation occurred, and resumed upon
recovery to baseline/grade 1, while a grade 3/4 prolongation of QTc
interval would mandate drug discontinuation.
Duration of study treatment
Patients could receive repeated cycles of treatment until disease
progression, unacceptable AE(s), patient’s decision to withdraw
from the study, or changes in the patient’s condition including
intercurrent illness rendering the continuation of study treatment
unacceptable.
Pharmacokinetic analysis
Blood samples for evaluation of SB939 PK were collected in cycle 1,
days 1 and 5 (days 1 and 3 for dose level 1) before dosing, then 0.5,
1, 1.5, 2, 3, 4, 6, 8 and 24–30h after dosing. Pre-dose PK
assessment was also performed on day 15 of treatment.
Whole blood was collected into a 3-ml blood tubes containing
K2EDTA anti-coagulant and centrifuged at 1000g for 10min at
41C. Plasma was kept as an aliquot and frozen at  801C. Levels of
SB939 in plasma were determined using a validated LC–MS/MS
method (Novotny-Diermayr et al, 2010). The samples were
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scentrifuged at 1200g for 10min at 41C, and the supernatant was
stored at  801C until analysis at MPI Research, Mattawan, MI,
USA. Pharmacokinetic parameters were calculated by a non-
compartmental method using WinNonlin 4.0 software (Pharsight
Corporation, Mountain View, CA, USA). Peak plasma concentra-
tion (Cmax) and time to peak concentration (Tmax) were estimated
from the plasma drug concentration–time curve. The elimination
half-life (T1/2) during the log-linear terminal phase was calcu-
lated from the elimination rate constant determined by a linear
regression analysis. The area under the concentration time curve
extrapolated to infinity (AUC0 N) was calculated by the log-linear
trapezoidal method for the observed values, with extrapolation to
infinity including at least three points on the terminal phase.
Pharmacodynamic analysis
Based on the preclinical data showing parallel changes in AcH3 in
PBMCs and tumour tissue, PBMCs were selected for study in the
phase I trial (Novotny-Diermayr et al, 2008; Yong et al, 2009).
Whole blood samples for PD evaluation were taken in cycle 1,
days 1 and 15 at pre-dose followed by 3 and 24h post-dose. For
each sample, blood was collected at room temperature in an
8-ml BD Vacutainer CPT tube (Becton, Dickson and Company,
Franklin Lakes, NJ, USA). Blood samples were processed in a
refrigerated centrifuge within 30min of collection to preserve
histone acetylation status. PBMCs were extracted from blood,
processed to pellet form and stored at  801C. Levels of AcH3 in
PBMCs were determined using a validated western blot technique
(Novotny-Diermayr et al, 2008).
RESULTS
Patient demographics, dose escalation and recommended
phase II dose
Thirty-nine patients were registered to this study but one patient
cancelled registration before treatment. The 38 treated patients
(Table 1) completed a total of 96 cycles of SB939 (median, 2; range,
1–12). Eight dose levels ranging from 10 to 90mg were evaluated
(Table 2, dose levels detailed in a chronological order). At the time
of this report, all patients are off study treatment.
At the 10mg dose level (5 days every 2 weeks), a patient was
observed to have a dose-limiting grade 3 bilirubin elevation, and
this event was initially attributed to drug. Thus, this dose level was
expanded by a further three patients, with no further DLTs
observed. Although the rise of bilirubin was temporally related to
SB939 administration, it was later deemed unrelated to treatment
and found to be related to a blocked stent.
At the 20mg dose level, one patient experienced grade
3 myositis, so again the dose level was expanded with no further
DLTs observed. No DLTs were seen at the 30, 50 and 70mg dose
levels during the escalation phase of the trial. At the 90mg
dose level however, two patients were treated and experienced
significant toxicity during cycle 1. The first patient had grade
3 fatigue and vomiting, while the dose for the second patient had to
be reduced to 70mg on days 15–19 due to intolerable grade
2 nausea, vomiting and fatigue. It was felt that further dosing of
patients at this level was inappropriate and 90mg was deemed the
MAD. As per protocol, the dose level of 70mg was then re-opened
for expansion. At this dose level, the first patient had grade
4 thrombocytopenia with a delay of day 15 dosing, while the
second patient had grade 3 fatigue. The third patient in the
expansion cohort had grade 2 nausea and vomiting and was unable
to complete the first week of treatment. These events suggested
that 70mg was poorly tolerated so an intermediate dose level of
60mg was open for evaluation. Seven patients were entered for
evaluation. One patient came off study after 1 week due to grade
3 ALT rise. This patient, tested negative for viral hepatitis serology
and autoimmune workup, had a prior history of transaminitis with
other drugs but a relationship with SB939 could not be excluded.
Aside from the patient with elevated LFTs, no other DLTs were
seen. This dose level (60mg) was thus concluded to be the RPTD.
Safety and compliance
All 38 treated patients were evaluable for non-haematologic,
haematologic and biochemical toxicities. The most frequently
reported AEs of all grades and those grades 3 or higher, separated
by dose levels and of at least possible relationship to SB939, are
described in Table 3 for non-haematologic events. The most
frequently reported, related non-haematologic AEs were fatigue
(53%), nausea (39%), vomiting (29%), anorexia (29%) and
diarrhoea (18%). The majority of these were grade 1 or 2 events,
Table 1 Patient characteristics
Characteristics No. %
a
No. of treated patients 38
Median age, years 62
Range 20–88
Sex
Male 23 61
Female 15 39
ECOG PS
07 1 8
12 6 6 8
25 1 3
Primary tumour site
Colon 15 39
Rectal 3 8
Neuroendocrine 3 8
Gastric 2 5
Head and neck 2 5
Non small cell lung cancer 2 5
Small bowel/appendix 2 5
Cervix 1 3
Renal 1 3
Melanoma 1 3
Ovary 1 3
Prostate 1 3
Salivary gland 1 3
Thyroid 1 3
Unknown primary/others 2 5
Measurable disease
Yes 36 95
No 2 5
Prior therapy
Chemotherapy 33 87
Hormone therapy 1 3
Immunotherapy 1 3
Radiotherapy 17 45
Other therapy 16 42
No. of prior chemotherapy regimens
05 1 3
11 3
21 0 2 6
31 4 3 7
45 1 3
52 5
71 3
Abbreviations: ECOG¼Eastern Cooperative Oncology Group; PS¼performance
status.
aPercentage values rounded to the nearest zero decimal point, therefore not
all values add up to a 100%.
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showever 4 patients experienced grade 3 fatigue, one patient had
grade 3 diarrhea while one patient had grade 3 vomiting. Other
grade 3 related events included myositis and syncope (one patient
each).
In terms of cardiac AEs, four patients had grade 2 QTc
prolongation documented in study, three in patients receiving a
dose level of 60mg or higher. One had a single elevated value
on day 1 cycle 1 that was not confirmed and received for the
remainder of their 5-day treatment at an unchanged dose. Two
patients had elevated QTc documented on day 5 of therapy, so
following the scheduled off-therapy week, the second 5-day
treatment was given at a reduced dose with no recurrence of
QTc prolongation. The fourth patient was complex. On Day 1 cycle
7 post-dose ECG showed frequent premature ventricular contrac-
tions and some episodes of bigeminy. This lasted about 48h and
on investigation it appeared that patient had had similar episodes
over the past 4 years. No cause was found for it. During periods of
arrhythmia, LVEF fell (values 20–39% compared with baseline of
55%). Troponin remained normal but QTc was slightly elevated in
some of the ECG tracings (in nine tracings done in the 10h after
day 1 dose, three patient had grade 1 elevation and one patient had
grade 2 (maximum QTc 475ms)). Patient was asymptomatic
throughout and was removed from the study for progressive
disease at the same time. It was unclear if this episode was study
drug related.
One patient experienced paroxysmal atrial tachycardia (grade 3,
unlikely related to study drug) 27 days after his last dose of SB939
associated with chest pain and dizziness. The patient had a slight
elevation in troponin, normal QTc and converted to sinus rhythm
with carotid massage. The relationship to SB939 was uncertain as
the patient had a significant history of coronary artery disease
and angina.
Thirty-six of 38 patients had documented anaemia on study
(grade 1¼25 patients, grade 2¼10 patients and grade 3¼1
patient). The number of patients experiencing other haematologic
AEs increased with dose, particularly at X60mg compared with
dose levels p50mg, respectively: thrombocytopenia 87 vs 22%;
granulocytopenia 60 vs 26%; lymphopenia 80 vs 57%. Biochemical
changes have been modest, all were grade 1 in patients with normal
baseline chemistries except one patient with myositis who
experienced a grade 3 CPK elevation, 3 patients at 60mg who
had grade 2 raised AST and hyperbilirubinemia and two patients at
that same dose level who had grade 3 ALT rise. Table 3 depicts
haematologic and biochemical AEs of all grades and those grades 3
or higher.
Dose reductions or omissions were seen occasionally in patients
treated from 10–60mg but were more frequently observed at 70
and 90mg dose levels (reductions in 2 of 6 and 2 of 2 patients,
respectively). At the RPTD of 60mg (n¼7), two patients had dose
reductions (transaminase rise and QTc prolongation), while two
patients had dose omissions (both due to alteration of liver
function tests).
Anti-tumour activity
Thirty-six of the 38 treated patients had measurable disease at
baseline. Of these, five patients were not assessable for response
because they received one cycle or less of treatment and were not
re-imaged. No objective tumour responses were observed. Ten
patients of the 31 evaluable (32%) had a best response of stable
disease (SD) while 21 (68%) patients had disease progression.
Patients with SD had a median duration of disease control for a
median of 5.7 months (range 1.8–10.8 months). Three patients, all
with history of metastatic colorectal carcinoma had disease
stabilisation of 46 months. These patients were treated at dose
levels 2, 3 and 4, with disease stabilisation achieved for a period of
8.1, 10.8 and 7.4 months, respectively, before stopping treatment
due to evidence of disease progression.
Pharmacokinetic analysis
Pharmacokinetic analysis showed SB939 was rapidly absorbed
(Tmax range of 1.0–2.5h) and has bi-exponential disposition.
The terminal half-life (T1/2) ranged between 6 and 9h. There was
no accumulation on Day 5 compared with Day 1. Mean AUC
increased dose proportionally between 10 and 90mg. A summary
of the Cmax and AUC0 N at different dose levels are represented in
Figure 1, while the full data on AUC0 N, T1/2, Cmax and Tmax are
detailed in Table 4.
Pharmacodynamic analysis
Increases in AcH3 were seen in patients treated in study with some
patients experiencing maximal increase at 3h post-treatment
and others at 24h post-treatment. There was no clear dose–PD
relationship noted. There were several PBMC samples that were
unsuitable for analyses in the mid-dose range, resulting in our
inability to define a dose–PD correlation. However, two indivi-
duals with the largest changes in levels were treated at the 60 and
70mg dose levels. No relationship between PD and disease
stabilisation or time on study could be discerned.
CONCLUSION
This study demonstrates that SB939 administered orally is
tolerable in patients with advanced solid tumours. The RPTD
was 60mg daily utilising a 5-day every 2 weeks schedule. The
Table 2 Dose level evaluated and DLT encountered
Dose level Dose Schedule Total no. of cycles
No. of patients with
DLT/total no. of patients treated DLT
1 10 3 days every 2 weeks 6 0/3
2 10 5 days every 2 weeks 16 1/6
a
3 20 5 days every 2 weeks 20 1/6 Grade 3 myositis
4 30 5 days every 2 weeks 19 0/4
5 50 5 days every 2 weeks 6 0/4
6 70 5 days every 2 weeks 5 0/3
7 90 5 days every 2 weeks 3 1/2
b Grade 3 fatigue Grade 3 vomiting
6 70 5 days every 2 weeks 4 3/3 Grade 4 platelets Grade 3 fatigue
5.5 60 5 days every 2 weeks 17 1/7
c Grade 3 ALT
d
Abbreviations: DLT¼dose-limiting toxicity; ALT¼alanine transaminase.
aGrade 3 bilirubin subsequently declared not drug related.
bNeither patient completed a full cycle.
cOne
patient had intolerable G2 nausea vomiting resulting in failure to receive further dose. Although this is not DLT per se according to protocol definition, we have classified this
event as a DLT due to the inability to resume treatment.
dOne patient did not complete cycle 1 because of ALT rise, however, it was not clear if this was entirely related to drug
since patient had elevated transaminases with prior treatment.
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sadministration of SB939 results in toxicities that included fatigue,
nausea, vomiting, anorexia and diarrhea. These symptoms have
been observed previously with this class of agents (Marshall
et al, 2002; Sandor et al, 2002; Kelly et al, 2005; Ryan et al, 2005;
Giles et al, 2006; Garcia-Manero et al, 2008; Siu et al, 2008). These
toxicities, however, were non-life threatening, and were effec-
tively addressed by dosing delay and dose reduction. While
QTc elevations were documented, none were grade 3. More data on
the frequency of QTc changes will be known following phase II
trials where monitoring during cycle 1 will be undertaken.
Although there was no objective tumour response to treatment,
31% of patients observed with SD (median 5.7 months), most of
whom had been heavily pre-treated. There were three colorectal
cancer patients with durable period of SD, but the numbers were
too small for any meaningful conclusion to be made.
When compared to the study by Yong et al, which gave SB939
every other day (three times per week), for 3 out of 4 weeks, our
dosing schedule appeared to have somewhat less myelosuppression,
but possibly more non-haematological AEs. However, comparison of
adverse effects between schedules in a non-randomised setting must
be viewed with caution. The schedule selected for phase II evaluation
is the every other day schedule, in part because both achieved
the same recommended dose and the every other day schedule
seemed to have less symptomatic toxicity, but also because more
continuous exposure might provide better therapeutic efficacy,
based on preclinical schedule data. Furthermore, the every other
day schedule explored by Yong et al had demonstrated a dose–PD
effect, strengthening the rational for choosing their dose schedule
over ours in further development of this drug.
The PK evaluations in this study have demonstrated favourable
pharmacologic properties of SB939. The drug was rapidly absorbed
within after oral administration, with a median Tmax ranging from
1 to 2.5h. Importantly, the drug had a long elimination half-life in
plasma of up to 9h, which compares favourably with the shorter,
Table 3 Related haematological and biochemical adverse events of all grades and those grade 3 or higher
a
Dose level
1 2 345 5 . 5 67
No. of patients
3 6 644762
Dose
10mg
b 10mg 20mg 30mg 50mg 60mg 70mg 90mg
Grades
All
grades
Grades
3/4
All
grade
Grades
3/4
All
grades
Grades
3/4
All
grades
Grades
3/4
All
grades
Grades
3/4
All
grades
Grades
3/4
All
grades
Grades
3/4
All
grades
Grades
3/4
General
Fatigue 0 0 2 020103061422
c 1
GI
Anorexia 0 0 0 0200010403010
Altered taste 0 0 0 0100000100010
Mucositis 1 0 1 0000000001000
Nausea 0 0 0 0200020504020
V o m i t i n g 000 010002040202
c 1
Diarrhoea 0 0 1 0101000410000
Constipation 0 0 0 0000000000000
Abdominal pain 0 0 0 0000000000000
Cardiac
QT prolongation 0 0 1 0000000101010
Ventricular bigemini 0 0 1
c 0000000000010
Ventricular arrythmias (PVCs) 0 0 1
c 0000000000010
Cardiac dysfunction 0 0 0 0000000000010
Supra ventricular arrythmia 0 0 0 0000000000010
Cardiac ischaemia 0 0 0 0000000000010
Cardiac arrythmia other 0 0 0 0000000100010
Metabolic
Creatinine (raised) 0 0 1 0102000202020
Alkaline phophatase (raised) 1 0 5 1412020603010
ALT (raised) 0 0 1 0202000421020
AST (raised) 1 0 3 0301020502020
Bilirubin (raised) 0 0 1 0101000200010
C P K N A N A 0 0111000001010
Hematologic
Anaemia 2 0 6 0514040706020
Leukopenia 1 0 2 0102010513110
Neutropenia 1 1 1 0102010503110
Lymphopenia 0 0 5 2202042634320
Thrombocytopenia 0 0 2 0100000506120
Others
Myositis 0 0 0 0110000000000
Syncope 0 0 0 0110000000000
Abbreviations: ALT¼alanine transaminase, AST¼aspartate transaminase, CPK¼creatine phosphokinase; PVCs¼premature ventricular contraction.
aGraded according to
CTCAE version 3.0.
b3 days every 2 weeks.
cOne or more SAE.
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s1–2-h half-lives of other HDAC inhibitors such as vorinostat and
belinostat (Kelly et al, 2005; Steele et al, 2008). The PK properties
as well as the RPTD of this study were also similar to the trial
carried out by our colleagues in Singapore (Yong et al, 2008). In
that study, the RPTD of SB939 was also 60mg in patients with solid
tumours and the AUC0 N, T1/2, Cmax and Tmax in that study were
comparable to ours.
The PD activity of HDAC inhibition arising from SB939
administration was explored in this study, utilising a validated
western blotting method. From cumulative data thus far, histone
acetylation does not show a linear correlation with dose. This may
be explained in part by the observation that several of the PBMC
samples in our study (in the mid-dose range) were not suitable for
PD analyses, resulting in the loss of dose–PD information. Despite
this, the highest AcH3 levels in our study were seen in patient
cohorts treated with higher doses of SB939, demonstrating the
proof of mechanism that this agent indeed leads to histone
deacetylation in the clinical setting. Furthermore, our results also
parallel the findings of our colleagues in Singapore where a
relationship between AcH3 levels and dose was observed (Yong
et al, 2009).
In our study, there is also a lack of correlation between AcH3
levels and anti-tumour activity. Although the loss of PD data set
point may contribute to this finding, there is increasing evidence
of non-histone protein substrates on which HDAC inhibitors exert
their anti-cancer effects. These include p53, Ku70, Hsp90, Stat3,
NF-kB and tubulin and the modulation of these substrates have a
role in regulating cell proliferation and survival (Lin et al, 2006).
Furthermore, phase I trial is not the setting in which one expects to
observe neither sufficient anti-tumour activities nor clear PD-anti-
tumour efficacy correlations.
Despite the promising preclinical activity of HDAC inhibitors, to
date these agents have been disappointing in solid tumours
clinically. The reasons for this are not completely clear, and may be
due to the validity and clinical relevance of HDAC as a therapeutic
target. However, other factors may also be important. For example,
the level and duration of target inhibition may be suboptimal
and the patient populations or tumour types studied may not have
been appropriately selected. All of these factors are important to
consider when developing drugs in this class, given that it is a
crowded field with at least two already approved agents.
With these factors in mind, phase II trials utilising SB939 as
monotherapy in translocation-associated sarcoma and prostate
cancer patients are underway. The rationale for SB939 treatment
in translocation-associated sarcomas is perhaps the best explained
in the synovial sarcoma, where fusions of the SS18 and SSX
(1, 2 and 4) genes are characteristic. These gene fusions are
associated with histone deacetylation and subsequent repression of
the tumour suppressor gene EGR1 (Soulez et al, 1999; van der Vlag
and Otte, 1999; Yochum and Ayer, 2001; Furuyama et al, 2004;
Terry et al, 2007). In vivo studies have shown that the use of HDAC
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Figure 1 (A) Mean Cmax and (B) AUC0–N of SB939 by dose level.
Table 4 Full data on AUC0 N, T1/2, Cmax and Tmax for SB939 at different
dose levels
Day 1 Day 3 or 5
Dose
level
Dose
(mg) Parameter Mean s.d. Mean s.d.
11 0
a AUC0–N (nghml
-1) 126.7 23.9 147.3 32.6
T1/2 (h) 7.1 0.2 8.3 0.7
Cmax (ngml
-1) 14.6 6.0 18.3 6.4
Tmax (h) 2.5 0.9 1.3 0.3
21 0 A U C 0–N (nghml
-1) 137.2 26.6 187.7 32.7
T1/2 (h) 8.6 1.5 8.1 2.5
Cmax (ngml
-1) 19.5 8.1 23.3 11.4
Tmax (h) 1.1 0.6 1.3 0.6
32 0 A U C 0–N (nghml
-1) 243.7 117.1 424.0 235.4
T1/2 (h) 5.9 2.4 7.7 0.6
Cmax (ngml
-1) 45.9 28.5 51.3 31.9
Tmax (h) 1.5 0.9 1.6 0.8
43 0 A U C 0–N (nghml
-1) 383.8 131.8 544.5 206.3
T1/2 (h) 8.6 1.7 8.8 2.1
Cmax (ngml
-1) 55.8 21.7 74.3 28.9
Tmax (h) 1.8 0.9 1.6 0.5
55 0 A U C 0–N (nghml
-1) 661.3 415.3 793.7 11.2
T1/2 (h) 5.6 1.3 8.9 1.2
Cmax (ngml
-1) 124.1 93.5 101.3 5.6
Tmax (h) 1.6 1.0 1.7 0.3
5.5 60 AUC0–N (nghml
-1) 1028.7 229.4 1625.2 405.5
T1/2 (h) 6.7 0.4 6.9 1.6
Cmax (ngml
-1) 209.6 55.3 262.5 65.9
Tmax (h) 1.2 0.5 1.3 0.4
67 0 A U C 0–N (nghml
-1) 1053.8 664.9 1134.3 678.0
T1/2 (h) 7.0 1.7 6.4 0.7
Cmax (ngml
-1) 178.2 122.2 159.7 118.8
Tmax (h) 1.6 0.4 1.5 0.5
79 0 A U C 0–N (nghml
-1) 1130.0 43.8 1229.0 —
T1/2 (h) 6.4 0.5 6.1 —
Cmax (ngml
-1) 228.9 7.1 116.0 —
Tmax (h) 1.0 0.0 1.5 —
a3 days every 2 weeks.
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sinhibitors leads to the reversal of the above aberrances (i.e.,
acetylation of histones with restoration of EGR1 expression) and
subsequently results in cell death (Lubieniecka et al, 2008).
Meanwhile, the TMPRSS2-ERG translocation, which has been
found to occur with regular frequency in prostate carcinomas,
appears to be associated with HDAC expression and is thus linked
with sensitivity to HDAC inhibitors (Tomlins et al, 2005; Iljin
et al, 2006; Bjorkman et al, 2008). Additionally, further
studies with SB939, especially in combination with other cytotoxic
and or targeted therapies, will help define the relevant treatment
schedule and best potential anti-tumour activity in specific tumour
types.
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